Mira Pharmaceuticals advances MIRA-55 toward IND-enabling studies after completing exploratory tox dosing in rats, dogs

Reuters2026/07/30 12:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Mira Pharmaceuticals moved two preclinical oral candidates, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction-related disorders, toward IND-enabling studies.
No clinical results were presented; exploratory 7-day repeat-dose safety studies in rats and dogs completed dosing and necropsy, with analyses still underway.
Early readouts are intended to support tolerability assessment and dose selection for upcoming GLP IND-enabling toxicology, not to establish efficacy.
Formulation, manufacturing, and CMC work continued to prepare for GLP toxicology and subsequent clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300800PRIMZONEFULLFEED9800651) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Mira Pharmaceuticals advances MIRA-55 toward IND-enabling studies after completing exploratory tox dosing in rats, dogs

You may also like

Crypto prices